Navigation Links
Tips from the Journals of the American Society for Microbiology
Date:9/22/2007

heir findings in the August 2007 issue of the Journal of Virology.

Following the declaration of global eradication of smallpox in 1979, vaccinations for the general public were discontinued. Today, the virus poses threat as an agent of biological warfare, leaving half of the worldwide population susceptible to serious disease or death in the event of an attack. Severe adverse effects resulting from the currently licensed Dryvax vaccine emphasize the need for new preventative methods.

Researchers developed two new vaccine candidates integrating the immune-enhancing protein Interleukin-15 (IL-15) and tested for efficacy in mice lethally challenged with a neurovirulent western reserve strain of vaccinia. Wyeth IL-15 included a strain of the vaccinia virus derived from the Dryvax vaccine and MVA IL-15 incorporated a modified strain of the vaccinia virus Ankara which is currently being considered as a substitute for the Dryvax vaccine. The Wyeth IL-15 vaccine resulted in a 1,000-fold reduction in lethality and highly increased cellular and humoral immune responses. Additionally, mice vaccinated with Wyeth IL-15 fully survived a lethal intranasal challenge ten months after vaccination. The second candidate MVA IL-15 also demonstrated greater immunogenicity and efficacy than Dryvax.

By integrating IL-15 cytokine into Wyeth and MVA strains, we have developed two smallpox vaccine candidates with greater immunogenicity and efficacy yet with more-attenuated virulence than the currently licensed Dryvax vaccine suitable for contemporary populations, say the researchers.

(L.P. Perera, T.A. Waldmann, J.D. Mosca, N. Baldwin, J.A. Berzofsky, S.K. Oh. 2007. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. Journal of Virology, 81. 16: 8774-8783).


First Animal Model Developed for Oral Infection of Human Poliovirus
'/>"/>

Contact: Carrie Patterson
cpatterson@asmusa.org
American Society for Microbiology
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. A disgusting video: U.S. companies sell out Americans
2. Northwestern Mutual, American Family make Computerworlds best IT workplaces
3. Brazilian bio-industry should impress American investors
4. CIO Leadership Series: Byrne Chapman, American Family Insurance
5. Metavante fires 180 North American workers
6. 300 millionth American no cause for eco-alarm
7. American Idol spurs music software
8. Healthcare software addresses "90 million" misclassified Americans
9. Technology and the "American" dream
10. Peters: Innovation the only edge that remains for American business
11. We are American No sex, please
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the ... today that an Investigational New Drug (IND) application ... rheumatoid arthritis has been accepted for review by ... In September 2012, MedImmune, the global ...
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)... BOSTON , March 26, 2015 /PRNewswire/ ... ), a global clinical research organization ... signed a definitive agreement to acquire all ... India ("QSI"), a leading provider of specialized ... refers to the collection, detection, assessment, monitoring, ...
(Date:3/25/2015)... pharmaceutical market is one of the most ... its absolute size, plus a growing economy and increasing ... Business Monitor International. The Russian market is set to ... market, with growth estimates around 10-15% annually reaching an ... About Green Cross Green Cross provides ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... SAN DIEGO, March 25 ADVENTRX Pharmaceuticals, Inc. (NYSE ... for the fourth quarter and year ended December 31, ... we advanced a new business model focused on lower-risk ... our new lead programs, but given the difficult economic ...
... RICHMOND, Va., March 25 Insmed Inc. (Nasdaq: ... today announced that on Monday, March 23, 2009, NASDAQ issued ... a minimum $1 closing bid price and those rules requiring ... The suspension will remain in effect through Friday, July 17, ...
... - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... enrolment in its U.K. clinical trial to evaluate ... in combination with gemcitabine (Gemzar(R)) in patients with ... The principal investigators are Dr. Johann de Bono ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... come out of research conducted on the edge of ... Olduvai Gorge in Tanzania since that produced by Louis ... a special issue of the prestigious Journal of ... of the Bernard Price Institute for Palaeontological Research, and ...
... on a unique vertebrate called the sea lamprey shows that ... development. These genes are paradoxically lost all throughout the developing ... or PGCs. The PGCs can be thought of as embryonic ... generation of lampreys. Based on computational analysis, a significant number ...
... rapidly create healthy clots and nearly double the survival ... research shows. "We knew an injection of these ... bleeding is stopped in time to increase survival following ... at Case Western Reserve University and leader of the ...
Cached Biology News:Dawn of humanity illuminated in special journal edition - 50 years after the Leakeys 2Research reveals unique solution to gene regulation 2Nanoparticles added to platelets double internal injury survival rate 2
Request Info...
... 2 , Maintenance 112 days/each ... , Immunizations/Boost injections x5 /each ... /each , Production bleed (25 ml ... Bleed ~ 100 ml blood (~50 ml serum) x1 ...
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
Biology Products: